These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29035388)

  • 1. A novel HER2 gene body enhancer contributes to HER2 expression.
    Liu Q; Kulak MV; Borcherding N; Maina PK; Zhang W; Weigel RJ; Qi HH
    Oncogene; 2018 Feb; 37(5):687-694. PubMed ID: 29035388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of H3K4me3 and H3K27me3 bivalent promotors in HER2+ breast cancer cell lines reveals variations depending on estrogen receptor status and significantly correlates with gene expression.
    Kaukonen D; Kaukonen R; Polit L; Hennessy BT; Lund R; Madden SF
    BMC Med Genomics; 2020 Jul; 13(1):92. PubMed ID: 32620123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards sustained silencing of HER2/neu in cancer by epigenetic editing.
    Falahi F; Huisman C; Kazemier HG; van der Vlies P; Kok K; Hospers GA; Rots MG
    Mol Cancer Res; 2013 Sep; 11(9):1029-39. PubMed ID: 23814024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A
    Wu VT; Kiriazov B; Koch KE; Gu VW; Beck AC; Borcherding N; Li T; Addo P; Wehrspan ZJ; Zhang W; Braun TA; Brown BJ; Band V; Band H; Kulak MV; Weigel RJ
    Mol Cancer Res; 2020 Jan; 18(1):46-56. PubMed ID: 31619506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in HER2 positive breast cancer epigenetics: Susceptibility and therapeutic strategies.
    Singla H; Ludhiadch A; Kaur RP; Chander H; Kumar V; Munshi A
    Eur J Med Chem; 2017 Dec; 142():316-327. PubMed ID: 28800870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer.
    Newman SP; Bates NP; Vernimmen D; Parker MG; Hurst HC
    Oncogene; 2000 Jan; 19(4):490-7. PubMed ID: 10698518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of activated enhancers and linked transcription factors in breast, prostate, and kidney tumors by tracing enhancer networks using epigenetic traits.
    Rhie SK; Guo Y; Tak YG; Yao L; Shen H; Coetzee GA; Laird PW; Farnham PJ
    Epigenetics Chromatin; 2016; 9():50. PubMed ID: 27833659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression.
    Lo PK; Lee JS; Liang X; Sukumar S
    Cell Signal; 2016 Oct; 28(10):1502-19. PubMed ID: 27377963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human epidermal growth factor receptor 2 inhibits activating transcription factor 7 to promote breast cancer cell migration by activating histone lysine demethylase 1.
    Lin J; Mao H; Ji Z; Lin W; Wang T
    J Cancer Res Ther; 2021 Nov; 17(5):1192-1201. PubMed ID: 34850767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 5' regulatory sequences of active miR-146a promoters are hypomethylated and associated with euchromatic histone modification marks in B lymphoid cells.
    Szenthe K; Koroknai A; Banati F; Bathori Z; Lozsa R; Burgyan J; Wolf H; Salamon D; Nagy K; Niller HH; Minarovits J
    Biochem Biophys Res Commun; 2013 Apr; 433(4):489-95. PubMed ID: 23528241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.
    Merry CR; McMahon S; Forrest ME; Bartels CF; Saiakhova A; Bartel CA; Scacheri PC; Thompson CL; Jackson MW; Harris LN; Khalil AM
    Oncotarget; 2016 Aug; 7(33):53230-53244. PubMed ID: 27449296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive epigenetic analyses reveal master regulators driving lung metastasis of breast cancer.
    Li K; Xu C; Du Y; Junaid M; Kaushik AC; Wei DQ
    J Cell Mol Med; 2019 Aug; 23(8):5415-5431. PubMed ID: 31215771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patients.
    Jeong YJ; Jeong HY; Lee SM; Bong JG; Park SH; Oh HK
    Oncol Rep; 2013 Nov; 30(5):2270-8. PubMed ID: 23969757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer.
    Dreijerink KMA; Groner AC; Vos ESM; Font-Tello A; Gu L; Chi D; Reyes J; Cook J; Lim E; Lin CY; de Laat W; Rao PK; Long HW; Brown M
    Cell Rep; 2017 Mar; 18(10):2359-2372. PubMed ID: 28273452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intron 1-Mediated Regulation of
    Jameson NM; Ma J; Benitez J; Izurieta A; Han JY; Mendez R; Parisian A; Furnari F
    Mol Cancer Res; 2019 Nov; 17(11):2208-2220. PubMed ID: 31444232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 silences tumor suppression in breast cancer cells by switching expression of C/EBPß isoforms.
    Arnal-Estapé A; Tarragona M; Morales M; Guiu M; Nadal C; Massagué J; Gomis RR
    Cancer Res; 2010 Dec; 70(23):9927-36. PubMed ID: 21098707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells.
    Delacroix L; Begon D; Chatel G; Jackers P; Winkler R
    DNA Cell Biol; 2005 Sep; 24(9):582-94. PubMed ID: 16153159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic mechanisms regulate the prostaglandin E receptor 2 in breast cancer.
    To SQ; Takagi K; Miki Y; Suzuki K; Abe E; Yang Y; Sasano H; Simpson ER; Knower KC; Clyne CD
    J Steroid Biochem Mol Biol; 2012 Nov; 132(3-5):331-8. PubMed ID: 22929011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of OCT4 induced by modulation of histone marks plays crucial role in breast cancer progression.
    Kar S; Patra SK
    Gene; 2018 Feb; 643():35-45. PubMed ID: 29203199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.